

1 **Malaria species prevalence among asymptomatic individuals in four regions of Mainland**

2 **Tanzania**

3 **Running Head: Non-falciparum malaria prevalence in Tanzania**

4 Zachary R. Popkin Hall<sup>1</sup>, Misago D. Seth<sup>2</sup>, Rashid A. Madebe<sup>2</sup>, Rule Budodo<sup>2</sup>, Catherine  
5 Bakari<sup>2</sup>, Filbert Francis<sup>3</sup>, Dativa Pereus<sup>2</sup>, David J. Giesbrecht<sup>4</sup>, Celine I. Mandara<sup>2</sup>, Daniel  
6 Mbwambo<sup>5</sup>, Sijenunu Aaron<sup>5</sup>, Abdallah Lusasi<sup>5</sup>, Samwel Lazaro<sup>5</sup>, Jeffrey A. Bailey<sup>6,7</sup>, Jonathan  
7 J. Juliano<sup>1</sup>, Julie R. Gutman<sup>8</sup>, Deus S. Ishengoma<sup>2,9,10</sup>

8

9 <sup>1</sup>Institute for Global Health and Infectious Diseases, University of North Carolina, Chapel Hill,  
10 NC, USA

11 <sup>2</sup>National Institute for Medical Research, Dar es Salaam, Tanzania

12 <sup>3</sup>National Institute for Medical Research, Tanga Center, Tanga, Tanzania

13 <sup>4</sup>The Connecticut Agricultural Experiment Station, New Haven, CT, USA

14 <sup>5</sup>National Malaria Control Programme, Dodoma, Tanzania

15 <sup>6</sup>Department of Pathology and Laboratory Medicine, Warren Alpert Medical School, Brown  
16 University, RI, USA

17 <sup>7</sup>Center for Computational Molecular Biology, Brown University, RI, USA

18 <sup>8</sup>Malaria Branch, Global Health Center, Centers for Disease Control and Prevention, Atlanta,  
19 GA, USA

20 <sup>9</sup>Harvard T. H. Chan School of Public Health, Boston, MA

21 <sup>10</sup>Faculty of Pharmaceutical Sciences, Monash University, Melbourne, VIC, Australia

22

23 **Key Words:** malaria, *Plasmodium malariae*, *Plasmodium ovale*, *Plasmodium vivax*, non-  
24 falciparum species, Tanzania, asymptomatic malaria

25 **Word Count:** 149 (abstract) | 1,609 (manuscript)

26 **Insert Count:** 2 figures, 1 table

27 **Abstract:** Recent studies point to the need to incorporate non-falciparum species detection into  
28 malaria surveillance activities in sub-Saharan Africa, where 95% of malaria cases occur.

29 Although *Plasmodium falciparum* infection is typically more severe, diagnosis, treatment, and  
30 control for *P. malariae*, *P. ovale* spp., and *P. vivax* may be more challenging. The prevalence of  
31 these species throughout sub-Saharan Africa is poorly defined. Tanzania has geographically  
32 heterogeneous transmission levels but an overall high malaria burden. In order to estimate the  
33 prevalence of malaria species in Mainland Tanzania, 1,428 samples were randomly selected  
34 from 6,005 asymptomatic isolates collected in cross-sectional community surveys across four  
35 regions and analyzed via qPCR to detect each *Plasmodium* species. *P. falciparum* was most  
36 prevalent, with *P. malariae* and *P. ovale* spp. detected at lower prevalence (<5%) in all four  
37 regions. *P. vivax* was not detected. Malaria elimination efforts in Tanzania will need to account  
38 for these non-falciparum species.

39

40 Tanzania has one of the highest malaria burdens in the world, accounting for 4.1% of  
41 global malaria deaths in 2021[1]. While most malaria cases in Tanzania and elsewhere in sub-  
42 Saharan Africa are caused by *Plasmodium falciparum*, four other *Plasmodium* species (*P. vivax*,  
43 *P. malariae*, *P. ovale curtisi*, and *P. ovale wallikeri*) are present to varying degrees. There is also  
44 data to suggest that these species have higher prevalence than previously known, and may  
45 become more prevalent as *P. falciparum* is controlled and ultimately eliminated[2–6] in line with  
46 the WHO goal of a 90% reduction in global malaria burden by 2030[7]. Non-falciparum malaria  
47 may require different control measures, due to major differences in biology, including different  
48 anopheline vectors with different seasonal peaks[8], relapse and/or chronic infections[9,10],  
49 lower parasitemia[11], and higher rates of asymptomatic infection[8].

50 Previous work in Mainland Tanzania has characterized non-falciparum prevalence in  
51 schoolchildren (5-16 years)[6] and non-falciparum positivity rates among symptomatic  
52 patients[12]. In schoolchildren, *P. ovale* spp. prevalence (24%) was similar to that of *P.*  
53 *falciparum* (22%)[6], while in symptomatic patients, *P. falciparum* was much more abundant  
54 than non-falciparum malaria, although *P. ovale* spp. positivity rates surpassed 5% in seven of  
55 ten regions[12]. In both studies, *P. malariae* was less common than either *P. falciparum* or *P.*  
56 *ovale* spp., and *P. vivax* was rare[6,12]. In this study, we characterize the prevalence of all  
57 malaria species among asymptomatic individuals across all ages in three regions with moderate  
58 and high malaria transmission intensity, and in children under five in one region with high  
59 transmission.

60 The study protocol was approved by the Tanzanian Medical Research Coordinating  
61 Committee (MRCC) of the National Institute for Medical Research (NIMR) and involved  
62 approved standard procedures for informed consent and sample deidentification. Additional  
63 details are described elsewhere[13]. Deidentified samples were considered non-human  
64 subjects' research at the University of North Carolina and Brown University.

65 A random subset of 1,428 dried blood spot (DBS) samples were drawn from a total of  
66 5,860 asymptomatic samples. 694 samples were drawn from a total of 2,647 collected from all  
67 age groups during cross-sectional community surveys in Kigoma (n=252/878, high  
68 transmission), Ruvuma (n=186/741, high transmission), and Tanga (n=256/1,028, moderate  
69 transmission) regions during the Molecular Surveillance of Malaria in Tanzania (MSMT) project  
70 in 2021[13]. The random subset was representative of the regional sample distribution ( $X^2$  (3,2)  
71 = 2.43, p (2 df) = 0.3, **Table S1**), but not representative of the age group distribution ( $X^2$  (3,2) =  
72 10.46, p (2 df) = 0.005, **Table S2**), or the sex distribution ( $X^2$  (2,2) = 43.65, p (1 df) < 0.001,  
73 **Table S3**). An additional 734 samples were drawn from 3,213 collected from children under five  
74 during cross-sectional household surveys for the group antenatal care project (GANC)[14,15] in  
75 Geita in 2021.

76 The molecular analyses used to detect *Plasmodium* spp. in each sample are described  
77 in detail elsewhere[12]. Briefly, we performed a separate 18S qPCR assay for each species,  
78 which allows for both the detection of each species as well as a semi-quantitative parasitemia  
79 estimate. For each region, we calculated prevalence for each species, including both single-  
80 species and mixed-species infections. Regional-level maps of prevalence for each species were  
81 created using the R package *sf* (version 1.0-9) based on shape files available from GADM.org  
82 and naturalearthdata.com accessed via the R package *rnaturalearth* (version 0.3.2)[16].  
83 Variation in species-specific prevalence by region and age group (young children <5 years,  
84 school-aged children 5-16 years, and adults >16 years, as previously described[12]) was  
85 assessed for significance with generalized linear models or ANOVA, as appropriate, in R.

86 Excluding the Geita participants who were all under five and whose ages were not  
87 recorded, the median age of the remaining 694 participants was 20 years (IQR 8-47) with a  
88 range of 6 months to 87 years. Including the Geita participants, children ( $\leq 16$  years old)  
89 constituted 74.2% of participants (n=1,060), while adults (>16 years old) constituted the

90 remaining 25.8% (n=368). Young children (<5 years old) comprised 77.9% (n=826) of the child  
91 participants, while the remaining 22.1% (n=234) were school-aged (5-16 years old). Sex  
92 identifications were available for 694 participants and female-skewed, with 505 female (72.8%)  
93 and 189 male participants (27.2%). 21.1% (n=301) of sampled individuals were RDT-positive.

94           Among all 1,428 samples analyzed, *P. falciparum* was detected in 34.2% (n=488, 95%  
95 CI: 31.7%-36.7%), *P. malariae* in 1.5% (n=22, 95% CI: 0.99%-2.4%), and *P. ovale* spp. in 3.4%  
96 (n=49, 95% CI: 2.6%-4.5%). *P. vivax* was not detected. *P. malariae* infections were nearly  
97 evenly split between single-species infections (45.5%, n=10/22) and mixed-species infections  
98 with *P. falciparum* (40.9%, n=9/22), with the remaining three (13.6%) being triple infections with  
99 *P. falciparum* and *P. ovale* spp. (**Table 1**). In contrast, most *P. ovale* spp. infections were mixed  
100 with *P. falciparum* (65.3%, n=32/49), with single-species infections being less common (28.6%,  
101 n=14/49) and triple infections comprising the remainder (**Table 1**). *P. malariae* had the highest  
102 median parasitemia at 164,080 p/μL (IQR 9,942-1,333,100 p/μL), followed by *P. falciparum* at  
103 55,200 p/μL (2,910-775,000 p/μL) and *P. ovale* spp. at 11,868 p/μL (1,271-70,840 p/μL).  
104 However, there was no significant difference in parasitemia by species (ANOVA p=0.9).

105

106

107

108

109

110


111 *Table 1* – Infection composition proportions for isolates infected with *P. malariae* and *P. ovale* spp.

<u>Infection Type</u>	<u>Count</u>	<u>Proportion</u>
<i>Pm</i>	10	45.5%
<i>Pm/Pf</i>	9	40.9%
<i>Pm/Pf/Po</i>	3	13.6%
All <i>Pm</i> Infections	22	
<i>Po</i>	14	28.6%
<i>Po/Pf</i>	32	65.3%
<i>Pm/Pf/Po</i>	3	6.1%
All <i>Po</i> Infections	49	

112 \*Sum of proportions may not equal 100% due to rounding.


113

114 All three species were detected in each region (**Figure 1**). Geita and Tanga had the  
115 highest *P. falciparum* prevalence (37.8% and 36.7%, n=278/734 and 94/256 respectively, **Table**  
116 **S4**). *P. malariae* was relatively rare in all four regions, with the highest prevalence in Tanga  
117 (3.1%, n=8/256) and the lowest in Geita (0.7%, n=5/734, **Table S4**). *P. ovale* spp. prevalence  
118 was slightly higher than *P. malariae* (3.2%-4.0%, n=6/186–10/252) in all regions except Tanga  
119 (2.3%, n=6/256, **Table S4**). There was significant variation (by ANOVA) in prevalence between  
120 regions for *P. falciparum* (p<0.001) and *P. malariae* (p=0.04) but not for *P. ovale* spp.



121  
122 Figure 1 – Maps of Tanzania showing A) location of study regions, B) *P. falciparum* regional prevalence, C) *P.*  
123 *malariae* regional prevalence, and D) *P. ovale* spp. regional prevalence. *P. vivax* was not detected, so is not mapped.

124 While age was a significant (GLM  $p < 0.001$ ) determinant of *P. falciparum* infection, there  
125 was no significant effect of age for either *P. malariae* or *P. ovale* spp. Age group was a  
126 significant (ANOVA  $p < 0.05$ ) determinant of infection likelihood for both *P. falciparum* and *P.*  
127 *malariae*, but not *P. ovale* spp. (**Figure 2**). While children were significantly ( $p < 0.05$ ) more likely  
128 than adults to have *P. falciparum*, adults were more likely to have *P. malariae* ( $p < 0.05$ , **Figure**  
129 **2**). There was no significant interaction between age group and region for either *P. falciparum* or  
130 *P. malariae*, but the interaction was nearly significant ( $p = 0.055$ ) for *P. ovale* spp.



131

132

133

134

135

136

137

138

139

Figure 2 – Tukey Analysis of Malaria Species Prevalence by Age Group. A total of 826, 234, and 368 were in the Young Children (<5 years), Schoolchildren (5-16 years), and Adult (>16 years) groups, respectively. The total number of samples per group for each species is shown in the X-axis labels while the number of positive samples for each group is shown in the bar labels. Comparisons marked with a \* are significant at the  $p < 0.05$  level. **Panel A** shows *P. falciparum* prevalence by age group. Significant pairwise comparisons are marked, while the other is insignificant. **Panel B** shows *P. malariae* prevalence by age group. One significant pairwise comparison is marked, while the others are insignificant. **Panel C** shows *P. ovale* spp. prevalence by age group. No pairwise comparisons are significant.

140

141

142

143

144

This study builds on previous research with schoolchildren and clinic patients to describe the prevalence of different malaria species within four regions of Mainland Tanzania. Although *P. falciparum* is the most prevalent species, both *P. malariae* and *P. ovale* spp. prevalence surpasses 3% in at least one region, and could increase as *P. falciparum* is locally eliminated. In contrast to a 2017 study on schoolchildren, which found *P. ovale* spp. prevalence to be similar



145 to *P. falciparum*[6], we found *P. ovale* spp. prevalence to be much lower than that of *P.*  
146 *falciparum*. In addition, the schoolchildren survey mostly identified *P. ovale* spp. as single-  
147 species infections and *P. malariae* as mixed with *P. falciparum*[6], whereas we found similar  
148 proportions of single-species and mixed-species *P. malariae* infections and most of our *P. ovale*  
149 spp. samples were mixed with *P. falciparum*. However, our sample sizes are small and may not  
150 necessarily be representative of the full picture, particularly in Geita where samples were only  
151 collected from children under 5 years old. In addition, our study only includes four regions, only  
152 one of which (Tanga) overlaps with the previous study, and we include a wider age range.

153 In Tanga, we may have found lower *P. ovale* spp. prevalence than the previous study  
154 due to the inclusion of adults, who are less likely to test positive for this species, whereas  
155 schoolchildren are a major asymptomatic infectious reservoir[17–19], although we did not  
156 replicate a significant difference in this study. In addition, the disruptions to malaria control  
157 caused by the COVID-19 pandemic, particularly in 2020-2021[20], could have an increase in *P.*  
158 *falciparum* prevalence. Indeed, there was no difference in the malaria prevalence in the villages  
159 of Magoda, Mambleo, and Mpapayu between 2019 (24.9%) and 2021 (24.5%, unpublished  
160 data). However, the prevalence dropped to 6.4% in 2022 (unpublished data), so further  
161 longitudinal study may clarify the impact of resumed intense *P. falciparum* control. However, the  
162 malaria prevalence in Tanga dropped from 34.8% to 26.2% between 2020 and 2021  
163 (unpublished data), so *P. falciparum* control in this region was likely effective during the course  
164 of this study.

165 Unlike in our study of symptomatic patients[12], we did not find schoolchildren to be  
166 significantly more likely to test positive for either *P. malariae* or *P. ovale* spp. Although not  
167 significant, this trend is present in *P. ovale* spp. prevalences in this study, so the lack of  
168 significance in these species is likely an artifact of small sample sizes (**Table 1, Figure 2,**

169 **Figure S1**). Our finding that *P. malariae* was significantly more prevalent among adults likely  
170 reflects the presence of chronic infections[10].

171 Although *P. falciparum* remains the most prevalent species in these four regions, *P.*  
172 *malariae* and *P. ovale* spp. are present in all four, whereas *P. vivax* is not detected. Achieving  
173 malaria elimination in Tanzania will require ongoing surveillance of these species. While  
174 standard treatments successfully clear *P. falciparum*, the 3.4% of patients in this study with *P.*  
175 *ovale* spp. may relapse. This study serves as a complement to previous studies focusing on  
176 schoolchildren and symptomatic patients to paint a full picture of the non-falciparum malaria  
177 landscape for communities in Mainland Tanzania. Ongoing analysis of samples collected in  
178 2022 and 2023 will allow us to detect temporal trends in prevalence, and forthcoming genomic  
179 analysis of *P. malariae* and *P. ovale* spp. isolates from Tanzania will inform our understanding  
180 of population structure and diversity in these species.

181 **Disclaimer:** The findings and conclusions in this report are those of the authors and do not  
182 necessarily represent the official position of the U.S. Centers for Disease Control and  
183 Prevention.

184 **Acknowledgements:** The authors wish to thank participants and parents/guardians of all  
185 children who took part in the surveillance. We acknowledge the contribution of the following  
186 project staff and other colleagues who participated in data collection and/or laboratory  
187 processing of samples: Raymond Kitengeso, Ezekiel Malecela, Muhidin Kassim, Athanas  
188 Mhina, August Nyaki, Juma Tupa, Anangisye Malabeja, Emmanuel Kessy, George Gesase,  
189 Tumaini Kamna, Grace Kanyankole, Oswald Osca, Richard Makono, Ildephonc Mathias,  
190 Godbless Msaki, Rashid Mtumba, Gasper Lugela, Gineson Nkya, Daniel Chale, Richard Malisa,  
191 Sawaya Msangi, Ally Idrisa, Francis Chambo, Kusa Mchaina, Neema Barua, Christian  
192 Msokame, Rogers Msangi, Salome Simba, Hatibu Athumani, Mwanaidi Mtui, Rehema Mtibusu,  
193 Jumaa Akida, Ambele Yatinga, and Tilaus Gustav. We also acknowledge the finance,

194 administrative and logistic support team at NIMR: Christopher Masaka, Millen Meena, Beatrice  
195 Mwampeta, Gracia Sanga, Neema Manumbu, Halfan Mwanga, Arison Ekoni, Twalipo Mponzi,  
196 Pendaël Nasary, Denis Byakuzana, Alfred Sezary, Emmanuel Mnzava, John Samwel, Daud  
197 Mjema, Seth Nguhu, Thomas Semdoe, Sadiki Yusuph, Alex Mwakibinga, Rodrick Ulomi and  
198 Andrea Kimboi. We are also grateful to the management of the National Institute for Medical  
199 Research, National Malaria Control Program and President's Office-Regional Administration and  
200 Local Government (regional administrative secretaries of the 14 regions, and district officials,  
201 staff from all 100 HFs and Community Health Workers from the 4 community cross sectional  
202 regions). Technical and logistics support from the Bill and Melinda Gates Foundation team is  
203 highly appreciated. The following reagents were obtained through BEI Resources, NIAID, NIH:  
204 Diagnostic Plasmid Containing the Small Subunit Ribosomal RNA Gene (18S) from  
205 *Plasmodium falciparum*, MRA-177; *Plasmodium vivax*, MRA-178; *Plasmodium malariae*, MRA-  
206 179; and *Plasmodium ovale*, MRA-180, contributed by Peter A. Zimmerman. Permission to  
207 publish the manuscript was sought and obtained from the Director General of NIMR.

208 **Competing Interests:** We declare no competing interests.

## 209 **Funding**

210 This work was supported, in part, by the Bill & Melinda Gates Foundation [grant number  
211 002202]. Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0  
212 Generic License has already been assigned to the Author Accepted Manuscript version that  
213 might arise from this submission. Data collection in Geita was funded by USAID/PMI through  
214 Jhpiego and CDC. JJJ also received funding from NIH K24AI134990.

## 215 **Authors' contributions:**

216 ZRPH, JAB, JJJ, and DSI conceived the study. ZRPH performed computational and  
217 epidemiological analyses and wrote the manuscript. MDS, RAM, RB, CB, and DP collected  
218 samples, extracted DNA, and performed qPCR analysis. CIM, JAB, JJJ, and DSI oversaw the

219 project. FF and DJG contributed data analysis. JRG oversaw data collection in Geita and  
220 assisted with statistical analysis. DM, SA, AL, and SL contributed data from NMCP and  
221 facilitated data collection. JAB, JJJ, JRG, and DSI edited the manuscript. All authors read,  
222 contributed to, and approved the final manuscript.

223 **Data availability:** Data is available upon reasonable request to the corresponding author.

## 224 **References:**

225 1. World Health Organization. World malaria report 2022. Geneva; 2022.

226 2. Akala HM, Watson OJ, Mitei KK, Juma DW, Verity R, Ingasia LA, et al. *Plasmodium*  
227 interspecies interactions during a period of increasing prevalence of *Plasmodium ovale* in  
228 symptomatic individuals seeking treatment: an observational study. *The Lancet Microbe*  
229 [Internet]. 2021 [cited 2022 Mar 31];2:e141–50. Available from:  
230 <https://linkinghub.elsevier.com/retrieve/pii/S2666524721000094>

231 3. Betson M, Clifford S, Stanton M, Kabatereine NB, Stothard JR. Emergence of Nonfalciparum  
232 *Plasmodium* Infection Despite Regular Artemisinin Combination Therapy in an 18-Month  
233 Longitudinal Study of Ugandan Children and Their Mothers. *J Infect Dis* [Internet]. Oxford  
234 Academic; 2018 [cited 2022 Mar 31];217:1099–109. Available from:  
235 <https://academic.oup.com/jid/article/217/7/1099/4791878>

236 4. Yman V, Wandell G, Mutemi DD, Miglar A, Asghar M, Hammar U, et al. Persistent  
237 transmission of *Plasmodium malariae* and *Plasmodium ovale* species in an area of declining  
238 *Plasmodium falciparum* transmission in eastern Tanzania. Marks F, editor. *PLoS Negl Trop Dis*  
239 [Internet]. Public Library of Science; 2019 [cited 2021 Apr 19];13:e0007414. Available from:  
240 <https://dx.plos.org/10.1371/journal.pntd.0007414>

241 5. Nguiffo-Nguete D, Nongley Nkemngo F, Ndo C, Agbor J-P, Boussougou-Sambe ST, Salako  
242 Djogbénou L, et al. *Plasmodium malariae* contributes to high levels of malaria transmission in a

- 243 forest–savannah transition area in Cameroon. *Parasites Vectors* 2023 161 [Internet]. BioMed  
244 Central; 2023 [cited 2023 Jan 30];16:1–10. Available from:  
245 <https://parasitesandvectors.biomedcentral.com/articles/10.1186/s13071-022-05635-7>
- 246 6. Sendor R, Mitchell CL, Chacky F, Mohamed A, Mhamilawa LE, Molteni F, et al. Similar  
247 Prevalence of *Plasmodium falciparum* and Non-*P. falciparum* Malaria Infections among  
248 Schoolchildren, Tanzania. *Emerg Infect Dis* [Internet]. 2023;29:1143–53. Available from:  
249 [https://wwwnc.cdc.gov/eid/article/29/6/22-1016\\_article](https://wwwnc.cdc.gov/eid/article/29/6/22-1016_article)
- 250 7. World Health Organization. Global Technical Strategy for Malaria 2016-2030 [Internet].  
251 Geneva; 2015. Available from: [https://www.who.int/malaria/publications/atoz/9789241564991/](https://www.who.int/malaria/publications/atoz/9789241564991/en/)  
252 [en/](https://www.who.int/malaria/publications/atoz/9789241564991/en/)
- 253 8. Tarimo BB, Nyasembe VO, Ngasala B, Basham C, Rutagi IJ, Muller M, et al. Seasonality and  
254 transmissibility of *Plasmodium ovale* in Bagamoyo District, Tanzania. *Parasit Vectors* [Internet].  
255 BioMed Central; 2022 [cited 2022 Feb 16];15:56. Available from:  
256 <https://parasitesandvectors.biomedcentral.com/articles/10.1186/s13071-022-05181-2>
- 257 9. Collins WE, Jeffery GM. *Plasmodium ovale*: Parasite and disease. *Clin Microbiol Rev*  
258 [Internet]. American Society for Microbiology; 2005 [cited 2022 Mar 31];18:570–81. Available  
259 from: <https://journals.asm.org/doi/full/10.1128/CMR.18.3.570-581.2005>
- 260 10. Oriero EC, Amenga-Etego L, Ishengoma DS, Amambua-Ngwa A. *Plasmodium malariae*,  
261 current knowledge and future research opportunities on a neglected malaria parasite species.  
262 *Crit Rev Microbiol* [Internet]. Taylor & Francis; 2021 [cited 2021 Jan 29];0:1–13. Available from:  
263 <https://www.tandfonline.com/doi/full/10.1080/1040841X.2020.1838440>
- 264 11. Roucher C, Rogier C, Sokhna C, Tall A, Trape JF. A 20-Year Longitudinal Study of  
265 *Plasmodium ovale* and *Plasmodium malariae* Prevalence and Morbidity in a West African  
266 Population. *PLoS One* [Internet]. Public Library of Science; 2014 [cited 2023 Mar 24];9:e87169.

- 267 Available from: <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0087169>
- 268 12. Popkin-Hall ZR, Seth MD, Madebe RA, Budodo R, Bakari C, Francis F, et al. Malaria  
269 species positivity rates among symptomatic individuals across regions of differing transmission  
270 intensities in Mainland Tanzania. medRxiv [Internet]. Cold Spring Harbor Laboratory Press;  
271 2023 [cited 2023 Nov 8];2023.09.19.23295562. Available from:  
272 <https://www.medrxiv.org/content/10.1101/2023.09.19.23295562v1>
- 273 13. Rogier E, Battle N, Bakari C, Seth MD, Nace D, Herman C, et al. Plasmodium falciparum  
274 pfhrp2 and pfhrp3 gene deletions among patients enrolled at 100 health facilities throughout  
275 Tanzania: February to July 2021. medRxiv [Internet]. Cold Spring Harbor Laboratory Press;  
276 2023 [cited 2023 Aug 7];2023.07.29.23293322. Available from:  
277 <https://www.medrxiv.org/content/10.1101/2023.07.29.23293322v1>
- 278 14. Emerson C, Ulimboka S, Lemwayi R, Kinyina A, Nhiga SL, Aaron S, et al. Women attending  
279 antenatal care as a sentinel surveillance population for malaria in Geita region, Tanzania:  
280 feasibility and acceptability to women and providers. Malar J [Internet]. BioMed Central Ltd;  
281 2023 [cited 2023 Jul 24];22:1–10. Available from:  
282 <https://malariajournal.biomedcentral.com/articles/10.1186/s12936-023-04480-y>
- 283 15. Gutman JR, Mwesigwa JN, Arnett K, Kangale C, Aaron S, Babarinde D, et al. Using  
284 antenatal care as a platform for malaria surveillance data collection: study protocol. Malar J  
285 [Internet]. BioMed Central Ltd; 2023 [cited 2023 Jul 24];22:1–10. Available from:  
286 <https://malariajournal.biomedcentral.com/articles/10.1186/s12936-023-04521-6>
- 287 16. Massicotte P, South A. rnatuarearth: World Map Data from Natural Earth [Internet]. 2023.  
288 Available from: <https://cran.r-project.org/package=rnatuarearth>
- 289 17. Abdulraheem MA, Ernest M, Ugwuanyi I, Abkallo HM, Nishikawa S, Adeleke M, et al. High  
290 prevalence of *Plasmodium malariae* and *Plasmodium ovale* in co-infections with *Plasmodium*

291 *falciparum* in asymptomatic malaria parasite carriers in southwestern Nigeria. Int J Parasitol  
292 [Internet]. Pergamon; 2022 [cited 2023 May 4];52:23–33. Available from:  
293 <https://linkinghub.elsevier.com/retrieve/pii/S0020751921002393>

294 18. Andolina C, Rek JC, Briggs J, Okoth J, Musiime A, Ramjith J, et al. Sources of persistent  
295 malaria transmission in a setting with effective malaria control in eastern Uganda: a longitudinal,  
296 observational cohort study. Lancet Infect Dis [Internet]. Elsevier; 2021 [cited 2021 Jul  
297 12];21:1568–78. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S1473309921000724>

298 19. Walldorf JA, Cohee LM, Coalson JE, Bauleni A, Nkanaunena K, Kapito-Tembo A, et al.  
299 School-Age Children Are a Reservoir of Malaria Infection in Malawi. PLoS One [Internet]. Public  
300 Library of Science; 2015 [cited 2023 May 4];10:e0134061. Available from:  
301 <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0134061>

302 20. Liu Q, Yan W, Qin C, Du M, Liu M, Liu J. Millions of excess cases and thousands of excess  
303 deaths of malaria occurred globally in 2020 during the COVID-19 pandemic. J Glob Health  
304 [Internet]. 2022;12:05045. Available from: <https://jogh.org/2022/jogh-12-05045>

305

306

307 *Supplemental Table 1 – Regional Distribution of Samples in Random Subset and Full Dataset*

<b>Region</b>	<b>Subset</b>	<b>Full Dataset</b>
Kigoma	252 (36.3%)	878 (33.2%)
Ruvuma	186 (26.8%)	741 (28.0%)
Tanga	256 (36.9%)	1,028 (38.8%)
<b>Total Samples</b>	<b>694</b>	<b>2,647</b>

308

309 *Supplemental Table 2 – Age Group Distribution of Samples in Random Subset and Full Dataset*

<b>Age Group</b>	<b>Subset</b>	<b>Full Dataset</b>
Young Children (<5 years)	92 (13.3%)	450 (17.0%)
Schoolchildren (5-16 years)	234 (33.7%)	962 (36.3%)
Adults (>16 years)	368 (53.0%)	1,235 (46.7%)
<b>Total Samples</b>	<b>694</b>	<b>2,647</b>

310

311 *Supplemental Table 3 – Sex Distribution of Samples in Random Subset and Full Dataset*

<b>Sex</b>	<b>Subset</b>	<b>Full Dataset</b>
Female	505 (72.8%)	1,568 (59.3%)
Male	189 (27.2%)	1,078 (40.7%)
<b>Total Samples</b>	<b>694</b>	<b>2,646*</b>

312 \*Sex was not reported for all individuals.

313




314

Supplemental Table 4 – Species Positivity by Region and Age Group

Region	Age Group	Pf-Positive Samples	Pm-Positive Samples	Po-Positive Samples	Total Samples
Geita*	Young Children	278 (37.9%)	5 (0.7%)	27 (3.7%)	734
	Schoolchildren	*	*	*	*
	Adults	*	*	*	*
	<b>All Ages</b>	<b>278 (37.9%)</b>	<b>5 (0.7%)</b>	<b>27 (3.7%)</b>	<b>734</b>
Kigoma	Young Children	7 (18.4%)	1 (2.6%)	1 (2.6%)	38
	Schoolchildren	26 (34.2%)	2 (2.6%)	7 (9.2%)	76
	Adults	26 (18.8%)	2 (1.4%)	2 (1.4%)	138
	<b>All Ages</b>	<b>59 (23.4%)</b>	<b>5 (2.0%)</b>	<b>10 (4.0%)</b>	<b>252</b>
Ruvuma	Young Children	0	0	0	23
	Schoolchildren	22 (37.9%)	2 (3.4%)	3 (5.1%)	58
	Adults	35 (33.3%)	2 (1.9%)	3 (2.9%)	105
	<b>All Ages</b>	<b>57 (30.6%)</b>	<b>4 (2.2%)</b>	<b>6 (3.2%)</b>	<b>186</b>
Tanga	Young Children	8 (25.8%)	1 (3.2%)	0	31
	Schoolchildren	44 (44%)	1 (1%)	1 (1%)	100
	Adults	42 (33.6%)	6 (4.8%)	5 (4%)	125
	<b>All Ages</b>	<b>94 (36.7%)</b>	<b>8 (3.1%)</b>	<b>6 (2.3%)</b>	<b>256</b>

315 \*Only children under five were enrolled in the study in Geita. Schoolchildren are defined as ages

316 5-16, and adults are all those >16 years.



317

318

Figure S1 – Samples included in analysis by age group and region.